Towards the Development of Mixed MT1-Agonist/MT2-Antagonist Melatonin Receptor Ligands (Q61781566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Annalida Bedini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Tomaso Guidi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Giorgio Tarzia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Valeria Lucini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Marilou Pannacci

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Franco Fraschini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

1099-1105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

Physiological and metabolic functions of melatonin

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

The chronobiotic properties of melatonin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin as a chronobiotic.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Role of melatonin in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Social stress affects circulating melatonin levels in rainbow trout

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Novel naphthalenic ligands with high affinity for the melatonin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Recent advances in melatonin receptor ligands.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

The Efficacy and Safety of the Melatonin Agonist beta-Methyl-6-Chloromelatonin in Primary Insomnia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin, the pineal gland and their implications for headache disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Antioxidant capacity of the neurohormone melatonin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin receptors step into the light: cloning and classification of subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Mammalian melatonin receptors: molecular biology and signal transduction.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Identification of the melatonin-binding site MT3 as the quinone reductase 2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin as a hypnotic: pro.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin mediates two distinct responses in vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Important amino acids for the function of the human MT1 melatonin receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Mutagenesis studies of the human MT2 melatonin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Chimeric melatonin mt1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Synthesis and evaluation of the antiovulatory activity of a variety of melatonin analogs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600133

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16955531%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference